Skip to content
VisionGate LogoVisionGate LogoVisionGate Logo
  • Home
  • About
    • Our Team
  • Our Technology
    • Non-Intrusive Testing
    • Patented Cell-CT Imaging
    • AI Powered Detection
  • Blog
    • News
    • Patents
    • Publications
    • Research
  • Contact

Blog

  • NewsFPO
  • Patents
  • Publications
  • ResearchFPO
  • November 12, 2024

    VisionGate Has Revised and Updated Its Website

    More Information

    News

  • August 26, 2024

    Patents from NeoPath, a predecessor to VisionGate are being highlighted at an exhibit at the Seattle Museum of History and Industry (MOHAI)

    More Information

    News

  • June 25, 2024

    #12,019,008:
    MORPHOMETRIC DETECTION OF MALIGNANCY ASSOCIATED CHANGE

    More Information

    Patents

  • May 8, 2024

    Dr. Alan Nelson presented on the topic: “How AI and IP Are Making a Difference in Early Cancer Detection” in a podcast sponsored by the Center for Intellectual Property Understanding (CIPU)

    More Information

    News

  • March 24, 2024

    IPAS Keynote speaker, VisionGate CEO Dr. Alan Nelson, at Northwestern Kellogg School of Management and Center for IP Understanding, Intellectual Property Awareness Summit 2024: AI-Driven Early Cancer Detection: Opportunities and Challenges

    More Information

    News

  • January 30, 2024

    #11,885,732:
    MORPHOMETRIC GENOTYPING OF CELLS IN LIQUID BIOPSY USING OPTICAL TOMOGRAPHY

    More Information

    Patents

  • November 12, 2023

    VisionGate appoints Neil Bush to its Board of Directors

    More Information

    News

  • November 12, 2023

    Dr. Ankit Bharat of the Northwestern University Feinberg School of Medicine to join VisionGate’s Medical Advisory Board

    More Information

    News

  • September 9, 2023

    VisionGate Presents at the World Conference on Lung Cancer for 2023 in Singapore: PneuVision® Sputum Test for Lung Cancer Achieves High Sensitivity in Detecting Both Squamous Cell Carcinoma and Adenocarcinoma

    More Information

    Research

  • September 9, 2023

    VisionGate Presents at the World Conference on Lung Cancer for 2023 in Singapore: PneuVision® Sputum Test for Lung Cancer Detects True Abnormal Cells in Non-cancer Patients with Near 100% Specificity

    More Information

    Research

12Next
visiongate logo retina logo

Follow Us

x icon
  • Home
  • About
  • Our Technology
Contact

© Copyright 2005 – 2025 | VisionGate, Inc | Milwaukee Web Design by Flipeleven | All Rights Reserved

3 Questions to Assess Your Risk

 Early detection of lung cancer is important to keeping you healthy and living your life to the fullest.

Has a family member had Lung Cancer? *
Have you smoked or been exposed to secondhand smoke? *

If you are over the age of 60 or answer "Yes" to any of the questions above, you may be at an increased risk.

This test is not a diagnosis but can help you recognize factors that may increase your risk of developing lung cancer. Next, You can subscribe to learn more from VisionGate. Then, you'll be redirected to a page of resources that can aid you in discussions with your doctor, or click here to access the page directly.

If you are above the age of 50 and answered "Yes" to any of the questions, you may be at an increased risk of developing lung cancer, but this is not a diagnosis. Use the link below to download resources that can help you talk to your doctor. Click Here to Download
We're sorry! There was an error submitting the test. Please try again later.

*No personal information is collected or saved through this form without your consent. Only your email and name will be saved if you opt-in.

visiongate logo
Contact
  • Home
  • About
  • Our Technology

© Copyright 2005 – 2025 | VisionGate, Inc | Milwaukee Web Design by Flipeleven | All Rights Reserved

Page load link
Go to Top